$Cm Life(CMLF)$ Total revenue decreased by $16.9 million, or 9%, from $196.2 million for the year ended December 31, 2019 to $179.3 million for the year ended December 31, 2020. 
Diagnostic test revenue decreased by $16.3 million, or 9%, from $191.7 million for the year ended December 31, 2019 to $175.4 million for the year ended December 31, 2020. The decrease was primarily attributable to a change in the mix of tests performed coupled with reduced reimbursement rates. Sema4 experienced an increase in volumes of 131%, primarily driven by the introduction of COVID-19 testing in May 2020. Despite these increased volumes, diagnostic test revenue decreased due to lower pricing on COVID-19 testing relative to other diagnostic tests and an overall decrease in average pricing on Women’s Health and Oncology testing.
我觉的1、2020对医疗检测机构来说是个不正常情况，应该区别对待；2、正常情况参考2019更有意义，其实2019年已经做到196million，如果没有疫情的话2020应该延续前几年的增长趋势。3、毛利ppt里2020就是22%，那时还没有2019和2018的数据，现在看起来2018在38%、2019在40%，差不多应该是正常的毛利率，如果接下去和医疗机构合作多的话毛利会提高。但实话实说这比我预期的要好，原本ppt里要从2020的22%逐步提高到2023的54%我心里是有怀疑的，现在既然知道2020有特殊情况，如果从38%-40%左右通过产品结构调整爬到50%以上我反而感觉更靠谱